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Abstract Psoriasis is a common chronic immune-medi-
ated inflammatory skin disorder and begins in childhood in
almost one-third of the cases. Although children present
with the same clinical subtypes of psoriasis seen in adults,
lesions may differ in distribution and morphology, and
their clinical symptoms at presentation may vary from
those reported by adult patients. Nevertheless, diagnosis of
psoriasis is primarily based on clinical features. Pediatric
psoriasis can have a profound long-term impact on the
psychological health of affected children. Additionally,
pediatric psoriasis has been associated with certain
comorbidities, such as obesity, hypertension, hyperlipi-
demia, diabetes mellitus and rheumatoid arthritis, making
early diagnosis and management essential. As guidelines
are lacking and most (systemic) treatments are not
approved for use in children, treatment of pediatric psori-
asis remains a challenge. A prospective, multicenter,
international registry is needed to evaluate these treatments
in a standardized manner and ultimately to develop inter-
national guidelines on pediatric psoriasis. This article
reviews current concepts in pediatric psoriasis including
epidemiology, clinical features, diagnosis, the role of
topical and systemic agents and the association with other
morbidities in childhood.
Key Points
In pediatric psoriasis patients, lesions may differ in
distribution and morphology, and their clinical
symptoms at presentation may vary from those
reported by adults.
There are currently no international standardized
guidelines for medical treatment of pediatric
psoriasis. Treatment is primarily based on published
case series, guidelines for adult psoriasis, expert
opinions and experience with these drugs in other
pediatric disorders.
Pediatric psoriasis has a high impact on the quality of
life of those affected.
There is increasing evidence suggesting an
association of pediatric psoriasis with certain other
morbidities, including hyperlipidemia, obesity,
hypertension, diabetes mellitus and rheumatoid
arthritis.
1 Introduction
Psoriasis is a common chronic immune-mediated inflam-
matory disorder affecting the skin, nails and joints in both
children and adults. The skin disorder is estimated to affect
2.0–3.5 % of the global population [1, 2]. A recent publi-
cation by Parisi et al. reported even higher percentages,
with ranges up to 8.5 % depending on the studied popu-
lation [3]. Psoriasis begins in childhood in almost one-third
of the cases [1, 4, 5], and the published incidence rates in
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children have more than doubled since 1970 [6]. Psoriatic
skin lesions are characterized by well defined erythematous
scaly plaques, and tend to have a chronic relapsing and
remitting course. Severity ranges from a few scattered
plaques to involvement of almost the entire body surface.
Psoriasis in children and adolescents can have a significant
impact on quality of life by interfering with self-esteem,
family and social relationships and school and work [7–9].
Children suffering from psoriasis also have a higher
prevalence of comorbidities, including obesity, diabetes
mellitus, hypertension, rheumatoid arthritis, Crohn’s dis-
ease and psychiatric disorders, compared with children
without psoriasis [1, 10–12]. Because of the burden of
disease and the associated comorbidities, early diagnosis
and management in children are essential.
2 Epidemiology
Prevalence rates vary slightly, depending on age, gender,
geographical location, definition of prevalence, study
design and case definition. Clinical presentation and pso-
riasis severity may also contribute to variation in preva-
lence and incidence numbers [3]. Although pediatric
psoriasis is not uncommon, limited epidemiology data are
available to date. It is estimated that approximately
30–50 % of adults with psoriasis developed psoriasis
before 20 years of age [5, 13, 14]. Gelfand et al. found that
the prevalence of psoriasis in childhood in the UK was
about 0.55 % in children aged 0–9 years and 1.37 % in
children aged 10–19 years [4]. This study also demon-
strated that the prevalence increased more rapidly in
females compared with males younger than 20 years. This
finding is probably not due to females paying closer
attention to their skin, but suggests an interaction between
sex and the development of the psoriasis phenotype in
young patients [4]. Comparable prevalence results have
been reported within the German (age 0–9, 0.18 %; age
10–19, 0.83 %) [1] and Dutch populations (age 0–10,
0.4 %; age 11–19, 1.0 %) [13]. In contrast to Europe,
pediatric psoriasis was almost absent in an epidemiological
study on childhood dermatoses performed in Asia [15, 16].
This worldwide geographical variation seems to reflect the
fact that psoriasis is a complex disease triggered by envi-
ronmental factors in genetically susceptible subjects [17].
The incidence of pediatric psoriasis has more than
doubled between 1970 and 2000. A study by Tollefson
et al. found the overall annual age- and sex-adjusted inci-
dence of psoriasis to be 40.8 [95 % confidence interval (CI)
36.6–45.1] per 100,000. An increase in triggering factors
for psoriasis such as psychosocial stress, infections and
being obese or overweight could be potential explanations
for this development [6]. Other exacerbating factors
include trauma or irritation of the skin and the use of
certain medications such as lithium, b-adrenergic antago-
nists and tumor necrosis factor alpha (TNF-a) inhibitors in
children with Crohn’s disease or juvenile idiopathic
arthritis (JIA) [18–20]. Most studies report no gender bias
in pediatric psoriasis. Tollefson et al. described a female to
male gender ratio of 1.10 [6]. These findings were similar
to other epidemiological studies from Australia, the USA,
India and China [5, 21–24]. However, a recent multicenter,
cross-sectional study performed in 181 children with pla-
que psoriasis in the USA reported a female to male gender
ratio of 1.48 [25]. This female predominance was also
demonstrated by others [26, 27]. The mean age of onset
varied from 8 to 11 years [6, 28–30]. Interestingly,
Augustin et al. demonstrated an almost linear increase in
prevalence rates between 0 and 18 years rather than a
‘‘peak of onset’’ [1].
About 30 % of individuals with psoriasis (children and
adults) have an affected first-degree family member [17].
The prevalence of psoriasis patients with an affected
family member is observed to be greater in early-onset
psoriasis (defined as psoriasis onset before the age of 16)
than in adult-onset psoriasis (defined as psoriasis onset
after the age of 16) [5, 29, 31, 32]. Chiam et al. compared a
Dutch and Singaporean group of children with psoriasis
and reported that more Dutch children than Singaporean
children had a first- or second-degree family member with
psoriasis (73.3 vs. 13.6 %) [26]. In an Australian popula-
tion, 71 % of children with psoriasis had a first-degree
relative with psoriasis. A positive family history of psori-
asis was reported in 51.4 % of pediatric psoriasis patients
in a multicenter, cross-sectional trial in the USA, with
affected members being first-degree relatives in 59.8 % of
those cases [25]. These differences point to the role of
genetic background within each population of patients with
juvenile psoriasis [23, 28].
3 Clinical Features
Although children present with the same clinical subtypes
of psoriasis seen in adults, lesions may differ in distribution
and morphology, and their clinical symptoms at presenta-
tion may vary from those reported by adults. In childhood,
typical erythematous plaques with overlying white scale
are often thinner and smaller and psoriasis lesions tend to
develop more often on the face and flexural areas. These
lesions are characterized by maceration and less prominent
scale [22, 28]. Despite these predilection sites, psoriasis
papules and plaques can develop on any skin area and are
usually symmetrically distributed [33]. Young children
usually present with a diaper rash that is unresponsive to
irritant diaper dermatitis treatment. Psoriatic diaper rash is
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seen in young infants and is characterized by sharply
demarcated, minimally elevated erythematous plaques in
the diaper area, involving the inguinal folds. The lesions
are often macerated, and can develop into a widespread
eruption within 1–2 weeks [32]. Morris et al. reported that
26 % of patients had a history of psoriasis diaper rash, but
the diagnosis of true psoriasis in these infants remains
controversial. Diaper psoriasis can be particularly difficult
to treat [23]. In older children, up to 75 % manifests with
chronic plaque psoriasis [26, 34]. This is the most common
type of psoriasis in children and adults and is characterized
by well defined erythematosquamous papules or plaques
with overlying silvery-white scale. The lesions vary in size
and develop primarily on the scalp, face and extensor
surfaces of the elbow and knee. The scalp is the most
frequently involved area and often the first site of presen-
tation in children [29, 35].
Guttate psoriasis is the second most common type of
psoriasis in children [21, 29]. Griffiths and Barker defined
guttate psoriasis as an acute form of psoriasis in which
papules erupt on the trunk approximately 2 weeks after a
b-hemolytic streptococcal or viral infection [17]. Accord-
ing to this definition, guttate psoriasis is self-limiting,
resolving within 3–4 months of onset [17]. It has been
reported that a proportion of individuals with guttate pso-
riasis eventually develop plaque psoriasis [22, 24, 25, 36,
37]. Mercy et al. suggested that the risk of severe disease is
higher if psoriasis started as guttate psoriasis which per-
sisted [25]. Prospective cohort studies are needed to further
determine features and percentages of children with guttate
psoriasis who develop plaque psoriasis.
Pustular psoriasis is seen in only 1.0–5.4 % of children
with psoriasis. In a minority of these patients, mutations of
the interleukin-36 (IL-36) receptor antagonist (IL36RN)
gene and subsequent upregulation of IL-1 production have
been identified [38]. Pustular psoriasis is characterized by
localized or generalized superficial sterile pustules and can
be accompanied by fever, malaise and arthralgias in the
case of classical von Zumbusch type. Although pustular
psoriasis is more common in adults, von Zumbusch pus-
tular psoriasis and pustular psoriasis with an annular con-
figuration occur more frequently in childhood [31, 39].
Other less common subtypes of psoriasis are inverse
psoriasis, palmoplantar psoriasis, isolated facial psoriasis,
linear psoriasis and erythrodermic psoriasis [17]. Erythro-
dermic psoriasis is characterized by erythema and scaling
on more than 90 % of the body surface area. The condition
is extremely rare in children and can be life-threatening
because of severe hypothermia, hypoalbuminemia and
cardiac failure [17, 32].
Psoriasis of the skin can be accompanied by changes of
the nail plate and nail bed. Nail changes have been reported
in up to 40 % of children with psoriasis and more often in
boys than in girls [25, 26, 33]. Nail changes can precede,
coincide with, or develop after skin psoriasis. Whether
these changes relate to patient age or disease severity vary
among studies [25, 40]. The most common presentation is
pitting of the nail plate. Other characteristics include oil
spots, onycholysis (distal separation of the nail plate from
the nail bed), subungual hyperkeratosis, onychodystrophy
and splinter hemorrhages [41]. Juvenile psoriatic arthritis
(JPsA) is another manifestation of psoriasis in children.
Because of difficulties in diagnosis and classification of
psoriatic arthritis in children, prevalence data range from 1
to 10 % of children with psoriasis [22, 25]. Approximately
7 % (range 0–11 %) of all patients with JIA appear to have
JPsA [42–46]. JPsA is included under the term JIA. Fol-
lowing the introduction of the International League of
Associations for Rheumatology (ILAR) criteria for JIA,
JPsA has become a better recognized inflammatory arthritis
in children. According to these criteria, JPsA can be
diagnosed in the presence of skin psoriasis, or in the
absence of a rash, if there are nail changes and/or a first-
degree relative with psoriasis [47]. Psoriatic arthritis is
more common in adults, with prevalence data up to 30 %
[34, 48, 49]. The peak of onset in childhood is between
ages 9 and 12, and the skin psoriasis often precedes pso-
riatic arthritis. Although a relationship between nail
involvement and psoriatic arthritis in adults has been sug-
gested, recent studies in both children and adults do not
support this correlation [25, 32, 50].
4 Diagnosis
In addition to the clinical features described above, chil-
dren often present with a thinner surface scale compared
with adults. When scraping off scales, punctuate bleeding
spots occur, a phenomenon known as the Auspitz sign. The
occurrence of lesions in areas of trauma, also called iso-
morphic response or Koebner phenomenon, and residual
pigmentation following healing of lesions are other typical
diagnostic features of psoriasis [34].
Although the diagnosis of psoriasis is primarily based on
clinical features, biopsy can help to confirm the diagnosis
in children with atypical presentations. Histological fea-
tures of psoriasis include parakeratosis, loss of the granular
cell layer, elongation of the rete ridges, neutrophilic
aggregates within the epidermis (microabscesses of
Munro), dilated blood vessels in the dermis, and perivas-
cular lymphocytic infiltrates [17, 51, 52]. These charac-
teristics may vary depending on site of biopsy, psoriasis
subtype, and whether children have been treated with
topical and/or systemic treatments. Given that the diagnosis
is usually made on the basis of morphology and distribu-
tion, a biopsy is virtually never performed, especially not in
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children. In atypical cases in which a diagnosis is required,
topical therapy should ideally be discontinued prior to
biopsy to avoid alteration of histological features [53].
Dermoscopy has become a standard diagnostic tool in
dermatology. Although this technique permits visualization
of morphological structures invisible to the naked eye, it is
not commonly used in the diagnosis of psoriasis. Lallas
et al., however, suggested that dermoscopy could distin-
guish psoriasis from other common skin diseases such as
dermatitis [55]. Dotted vessels regularly distributed over a
light red background and diffuse superficial white scales
are typical dermatoscopic characteristics of a psoriasis
plaque [54, 55]. Further research is warranted to determine
the added value of dermoscopy in diagnosis and predicting
response to treatment.
5 Management
Treating pediatric psoriasis can be challenging and requires
careful compliance to a specific treatment regimen. Poor
treatment adherence is rampant in psoriasis, in particular to
topical agents [56, 57]. Educating the patient and family on
the chronicity of psoriasis, triggering factors, and treatment
modalities is important, in addition to prescribing treat-
ment. Timing of the first return visit may be a practical tool
to enhance patient adherence [29]. Return visits can induce
‘‘white coat compliance’’ in which the expectation of fre-
quent monitoring can enhance patients’ use of medication
[58]. Psychosocial support is another important component
of therapy for children with psoriasis [7].
There are currently no international standardized
guidelines for medical treatment of pediatric psoriasis. To
date, treatment is primarily based on published case
reports, guidelines for adult psoriasis, expert opinions and
experience with these drugs in other pediatric disorders.
The range of psoriasis treatments has been expanded dur-
ing the past several years, and multiple topical agents,
phototherapy and systemic and biological agents are
available to date [53]. Several factors need to be taken into
account when selecting a specific treatment, e.g., age,
quality of life, severity of psoriasis, location of psoriasis,
type of psoriasis, tolerability, safety and patient preferences
[59–61].
6 Topical Treatments
The majority of children with psoriasis can be managed
with topical treatment, which is considered first-line ther-
apy in psoriasis. However, most are not approved for
pediatric use, requiring off-label prescribing [61]. The most
commonly used topical agents will be reviewed below. The
vehicle for treatment is important and depends on the
location of psoriasis, lesional characteristics, and patient
preference [62]. Available vehicles include creams, oint-
ments, foams, gels and lotions.
6.1 Topical Corticosteroids
Topical steroids are the most commonly prescribed medi-
cations to treat psoriasis in all age groups. Steroids are
available in a wide variety of strengths and vehicles. In
adults, low- to mid-potency corticosteroids are used in
facial, flexural and genital lesions, with use of high-po-
tency corticosteroids in combination with penetration
enhancers in areas of thick skin, such as the palms and the
soles. In a systematic review on treatments in childhood
psoriasis, three studies on the efficacy and safety of topical
corticosteroids were reported [63]. The total number of
treated children in these three studies was 20, with a
treatment period of 2 weeks. Based on these studies, it was
concluded that halobetasol cream 0.05 % and clobetasol
propionate emulsion 0.05 % are efficacious in pediatric
plaque psoriasis. Reported side effects were relatively mild
in the treatment period of 2 weeks, with burning sensation
at the site of application or skin atrophy reported most
frequently [63–65]. Apart from these studies with the
strongest steroids available, no reports on the efficacy and
safety of topical corticosteroids in pediatric psoriasis were
found. Potential side effects of (prolonged) use in adults are
skin atrophy/striae, telangiectasias, acneiform dermatitis,
tachyphylaxis, periorificial dermatitis, hypertrichosis and,
less commonly, suppression of the hypothalamic–pitu-
itary–adrenal axis. Therefore, corticosteroids should be
used with caution through intermittent or rotational use to
limit possible side effects [29, 32].
6.2 Vitamin D Analogs Alone and in Combination
with Topical Corticosteroids
Studies with topically administered calcipotriol and cal-
citriol have shown efficacy in pediatric psoriasis patients
with only mild side effects [63]. Localized skin irritation
and pruritus are the most common side effects, and use of
these preparations is therefore avoided on areas with
thinner skin, such as the face, genital and flexural areas
[53]. However, calcitriol ointment has been found to be
less irritating than calcipotriol ointment if used in intert-
riginous psoriasis [29, 62]. Systemic absorption of vita-
min D and increasing calcium levels could theoretically
occur, but are unlikely if used appropriately [34]. Use of
up to 45 g/m2/week in pediatric patients with psoriasis
does not seem to influence calcium levels in children from
3 to 14 years [66, 67]. Vitamin D analogs are not rec-
ommended in children under the age of 2 years [62].
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Although vitamin D analogs may be used as
monotherapy, they are often prescribed in combination
with topical corticosteroids, leading to drug synergy and a
steroid-sparing effect [32, 68]. In order to avoid separate
applications and to enhance patient compliance, a com-
mercially available compounded formulation containing
calcipotriol and betamethasone dipropionate has been
developed. Three studies describe the efficacy and safety
of this formulation in pediatric psoriasis [69–71]. In a
prospective study with a clinical practice cohort, 73
children (aged 3–18 years) with plaque type psoriasis
were treated with calcipotriol/betamethasone dipropionate
ointment once daily for 4 weeks and 4 days a week
thereafter, with a median treatment duration of 35 weeks.
The greatest effect of calcipotriol/betamethasone oint-
ment was achieved within the first weeks. Continued
treatment seemed to stabilize psoriasis in these children.
Five children reported an adverse event, most commonly
the development of striae [69]. A multicenter, open-label
study by Gooderham et al. found calcipotriol/betametha-
sone dipropionate gel applied once daily for 8 weeks in
adolescents (aged 12–17 years) with moderate to very
severe plaque psoriasis to be well tolerated and effective.
[70]. Oostveen et al. demonstrated the effectiveness of
calcipotriene/betamethasone dipropionate gel in pediatric
scalp psoriasis (patient ages 4–17 years) within the first
12 weeks of treatment (84 treatment episodes), with
maintenance of this effect through the 48 weeks of fol-
low-up. Striae of the skin (arms, trunk and legs) were
described in three patients [71].
6.3 Calcineurin Inhibitors
In adults, tacrolimus (0.03 and 0.1 %) and pimecrolimus
(1 %) have proven to be effective on psoriasis lesions on
the face, genitalia and flexures and are a good alternative
for psoriasis in these areas sensitive to the adverse effects
of long-term topical steroid use [72]. The efficacy and
safety of tacrolimus 0.1 % applied twice daily in pediatric
patients with psoriasis was evaluated in two nonrandom-
ized clinical trials. All patients had cleared or improved
substantially with the use of tacrolimus ointment within
the first 30 days of treatment. The only reported adverse
effect was pruritus in one patient [73, 74]. There is cur-
rently not enough evidence for the use of pimecrolimus
1 % cream in the pediatric psoriasis population, as this
was only described in two patients [63]. Concomitant
treatment with phototherapy and excessive sun exposure
should be avoided because of the possible increased risk
for skin cancer and lymphoma. However, further research
is warranted to study possible long-term adverse effects
[60].
6.4 Dithranol
Dithranol, also referred to as anthralin, is a topical agent
with both anti-inflammatory and anti-proliferative proper-
ties and no significant systemic absorption. It is an effec-
tive and safe treatment option for pediatric psoriasis [32,
36]. Short-contact dithranol at higher concentrations
(0.1–3 %) and applied for shorter periods of time
(10–30 min daily until irritation develops) maintains
treatment efficacy but diminishes the risk of irritation and
staining. Short-contact dithranol involves an intense treat-
ment schedule and is preferably administered in a day care
setting. In a retrospective study determining the position of
dithranol in the treatment of pediatric psoriasis, a good or
excellent result was achieved in 73.2 % of the patients. A
median treatment period of 2 months was needed to
achieve a median duration of remission of 5.5 months [75].
Recently, Oostveen et al. demonstrated the efficacy and
safety of short-contact dithranol therapy in a prospective
observational study in 34 pediatric patients [76]. A sig-
nificant reduction in Psoriasis Area and Severity Index
(PASI) score of 69.3 % was found, and the only reported
adverse event was irritation of the skin. The efficacy and
safety of short-contact dithranol treatment in day care with
telemedicine (one visit per week and one scheduled video
call via Skype) compares well to administration in a regular
day care setting (two visits per week) [76]. Although
effective and safe to use in pediatric patients, dithranol can
stain clothes and cause local skin irritation, particularly in
facial, flexural, erythrodermic or pustular psoriasis [34, 36].
6.5 Phototherapy
Several studies have reported the use of phototherapy in
pediatric psoriasis. Narrow band ultraviolet B light
(nbUVB) seems to be an effective and well tolerated
alternative treatment in pediatric patients with plaque and
guttate psoriasis [63, 77] that is poorly controlled with
topical therapy. However, logistics and frequency of
appointments could be an issue for some patients and their
parents. In 2011, a retrospective study in pediatric psoriasis
patients (range 2–18 years) demonstrated complete clear-
ance in 51 % and a good response (at least 75 %
improvement) in 41 % of the children. Mean duration of
treatment was 3.3 months [78]. Only a small number of
pediatric patients were treated with psoralen plus UVA
radiation (PUVA), which is now rarely used in children
because of long-term toxicity [53, 79]. Short-term side
effects of phototherapy include erythema, burning, pruritus
and blistering. Anxiety can also be a significant problem in
children [80]. Although long-term side effects (e.g., car-
cinogenesis, photoaging) of nbUVB and PUVA have been
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seen in adults [81], current evidence is heterogeneous and
needs to be interpreted with caution [82, 83]. There is a
need for long-term follow-up in order to further clarify
these associations, especially in the pediatric population
[63, 79].
7 Systemic Treatments and Biologics
In children with moderate to severe psoriasis recalcitrant to
topical treatment, systemic treatments are indicated [63].
However, the choice of agent remains a challenge because
of the limited number of clinical trials and lack of guide-
lines in this age group [84]. Most of the systemic treat-
ments are not approved to use in children and are used off-
label. Therefore, daily practice clinical decision making
can be complicated and challenging. A systematic review
on the efficacy and safety of all systemic treatments in
pediatric psoriasis by van Geel et al. provided evidence-
based recommendations for the use of these agents in the
pediatric psoriasis population [85].
7.1 Methotrexate
Methotrexate (MTX) has been approved for treatment of
severe psoriasis in adults. However, in children, MTX is
only approved for treatment of JIA, inflammatory bowel
disease (IBD) and certain malignancies [29, 86]. The use of
MTX in pediatric psoriasis has also been studied [85]. A
recent analysis of a prospective registry demonstrated the
safety and efficacy of oral and/or subcutaneous MTX in 25
children with plaque psoriasis [87]. Based on the available
evidence, MTX is considered to be the systemic treatment
of choice in children with moderate to severe plaque pso-
riasis and its variants [85, 87, 88]. MTX can be adminis-
trated either orally or subcutaneously [89]. To date there is
no consensus about MTX dosing regimen and treatment
duration in pediatric psoriasis. As soon as therapeutic
control is achieved, it is recommended to taper the dose to
an effective but lower maintenance dose in order to reduce
side effects [86]. Folic acid is routinely administered to
further reduce these side effects. However, optimal dose
and timing of folic acid administration is still unclear [84,
90, 91].
The most common side effects include nausea, vomit-
ing, fatigue, stomatitis and abnormal liver function tests.
Bone marrow suppression, pulmonary toxicity, infections
and hepatotoxicity including liver fibrosis have been rarely
reported in children [60, 86, 87, 92]. Bone marrow sup-
pression is potentially life-threatening, and generally
occurs within the first months of treatment. Laboratory
testing is done on a regular basis to monitor for these
potential side effects. In addition, concomitant use of
medications such as nonsteroidal anti-inflammatory drugs
and trimethoprim/sulfamethoxazole needs to be avoided as
these can interact with MTX and increase its potential
toxicity [29, 86]. Alcohol is also strongly discouraged
during MTX use because of its hepatotoxicity [92].
7.2 Cyclosporine
Cyclosporine is an immunosuppressant drug approved for
treatment of psoriasis in adults. It has a rapid onset of
action (2–4 weeks) and is therefore considered to be an
ideal drug for controlling unstable disease in this popula-
tion [89, 93–95].
To date, the efficacy of cyclosporine in pediatric psori-
asis remains unclear [85]. Children may require higher
doses than recommended in adults, because of differences
in pharmacokinetics and the greater body surface area to
weight ratio in children [89, 94, 96]. Reported side effects
include nephrotoxicity, hypertension, nausea and diarrhea.
Because evidence in children is limited, the lowest possible
dose and shortest treatment period should be used. Close
monitoring of blood pressure and renal function is required
[86, 90]. The long-term risk of non-melanoma skin cancers
has also been described. Concomitant phototherapy should
be avoided to further reduce the risk of these malignancies
[29, 60].
7.3 Retinoids
The efficacy and safety of retinoid treatment in pediatric
psoriasis treatment has been shown primarily in pustular
and erythrodermic psoriasis [85]. Etretinate was previously
used but is no longer commercially available, and it has
been replaced by acitretin, its active metabolite. The use of
acitretin has only been described in a few children with
psoriasis [97, 98]. Mucocutaneous side effects such as
cheilitis, xerosis, epistaxis, skin fragility, hair loss and
ocular toxicities have frequently been reported [60, 85].
Laboratory follow-up is needed to monitor for elevated
liver enzymes and triglycerides. In addition, prolonged
retinoid use has been associated with diffuse idiopathic
skeletal hyperostosis, premature epiphyseal closure (at high
doses) and decreased bone mineral density [29, 99]. Due to
the teratogenicity of oral retinoids and concerns about
delayed clearance, the use in adolescent girls should be
considered carefully. Pregnancy must be avoided until at
least 3 years after stopping therapy [34, 36].
7.4 Fumaric Acid Esters
Fumaric acid esters (FAE) have a broad range of
immunomodulatory effects and are registered for the
treatment of moderate-to-severe plaque psoriasis in adults
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in Germany [90]. In adults, doses can be titrated to a
maximum of 720 mg daily, depending on clinical response
and tolerability [84, 90, 100, 101]. Although data on
pediatric use are limited, a retrospective case series of 14
children demonstrated complete clearance of psoriasis in
36 %, good improvement in 7 %, partial response in 21 %
and non-response in 36 % of pediatric patients. The median
duration of treatment was 10 months (range 1–80 months).
A starting dose of dimethylfumarate of 30 mg was given,
and was increased to a maximum daily dosage of 720 mg
on the basis of clinical response and tolerability [100].
Reported side effects include flushing, gastrointestinal
complaints, eosinophilia, transient shifts in leukocyte
counts, and elevated hepatic transaminases. Mild protein-
uria and increased serum creatinine levels may also occur
[100, 102–104]. Although evidence to date is limited, FAE
can also be considered in pediatric psoriasis if MTX is
ineffective or contraindicated [85].
7.5 Biologics
Biologics are relatively new pharmacological agents that
target specific mediators of the inflammatory cascade in
psoriasis, including TNF-a and IL-12/23. Biologics offer
more favorable dosing regimens and require less frequent
lab monitoring than conventional systemic therapies.
International guidelines about the use of biologics in
pediatric psoriasis are lacking [89]. Moreover, biologics
have been associated with complications in both children
and adults, including opportunistic infections, reactivation
of latent tuberculosis and malignancies, in particular lym-
phomas. Although these complications are rare, and pri-
marily reported in patients with arthritis, IBD or
sarcoidosis, the advantages must be balanced with some
caution [89, 106]. As long-term safety data are lacking,
potential risks should be discussed with the patient and
parents prior to decision making.
7.5.1 Etanercept
Although approved in Europe and Canada for children
aged 8 years and older, the US Food and Drug Adminis-
tration (FDA) has yet to approve psoriasis as an indication
for etanercept in the pediatric population [86, 89, 107]. In
2008, a double-blind, multicenter, phase III, randomized
controlled trial evaluated the safety and efficacy of etan-
ercept in children aged 4–17 with moderate-to-severe pla-
que psoriasis. Etanercept was well tolerated and
demonstrated a significantly reduced severity of disease at
week 48 and 96. Most common short-term side effects
included infections such as pharyngitis, bronchitis and
gastroenteritis. No deaths, cancers, opportunistic
infections, tuberculosis or demyelination events were
reported [105, 108]. Although long-term etanercept treat-
ment seems well tolerated in children with JIA, the asso-
ciation between TNF blockers and development of
malignancy remains unclear [109, 110]. Therefore, etan-
ercept is still considered to be a third-line drug in severe
and/or recalcitrant psoriasis in children [85, 89]. A clinical
trial evaluating the long-term safety and efficacy of etan-
ercept for treatment of pediatric psoriasis is ongoing [111].
7.6 Other Biologics and Future Prospects
Other biologics that could play a role in pediatric psoriasis
in the near future are adalimumab, infliximab and ustek-
inumab. In 2008, the FDA approved adalimumab for the
treatment of JIA in children aged 4 years and older. Cur-
rently, this biologic is also used off-label for pediatric
psoriasis, IBD and uveitis [60, 106]. Only two case reports
describe the use of adalimumab in pediatric psoriasis [85].
In these patients, adalimumab was prescribed after failure
of other systemic agents and demonstrated a favorable
outcome [112, 113]. A multicenter, randomized, double-
blind study evaluating the efficacy of adalimumab versus
methotrexate in pediatric patients aged 4–17 years with
chronic plaque psoriasis has been completed [114],
although results are not currently available. Adalimumab
was recently granted marketing authorization in the EU for
severe chronic plaque psoriasis in children aged 4 years
and older who have had an inadequate response to or are
inappropriate candidates for topical treatment and
phototherapies.
Infliximab, which is the only TNF inhibitor administered
by infusion, is FDA approved for the treatment of Crohn’s
disease in children aged 6 years and older [106]. In pedi-
atric psoriasis, only four anecdotal case reports are avail-
able [85, 89, 111]. Ustekinumab was recently FDA
approved for the treatment of adult psoriasis [89]. There
are currently three case reports describing the use of
ustekinumab in pediatric patients with psoriasis. All had an
excellent response to ustekinumab, with two achieving
total clearance at week 8 [115–117]. Future research is
needed to determine efficacy and safety profiles and the
role of these agents in the treatment of pediatric psoriasis.
A phase III, multicenter, randomized, double-blind, pla-
cebo-controlled trial on the efficacy and safety of ustek-
inumab in the treatment of adolescents with plaque
psoriasis (CADMUS trial) was recently completed.
Respectively, 78.4 and 80.6 % of adolescents (aged 12–18)
receiving half-standard dosage (0.375 mg/kg) and standard
dosage (0.750 mg/kg) achieved PASI75 at 12 weeks as
compared with 10.8 % of participants receiving placebo
[111, 118].
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8 Comorbidities in Pediatric Psoriasis
As in adult psoriasis, recent studies suggest the association
of pediatric psoriasis with certain comorbidities. In an
analysis of German health insurance data, a twofold
increased risk of hyperlipidemia, obesity, hypertension,
diabetes mellitus and rheumatoid arthritis was found in
psoriasis patients under 18 years of age, as compared with
healthy controls. Crohn’s disease is noted four times more
often as compared with unaffected controls [1]. Similar
results have been found in a smaller insurance company
database [119].
Obesity as a comorbidity of psoriasis has been the focus
of much investigation. Koebnick et al. demonstrated that
children who were overweight, moderately obese and
extremely obese had 1.31-, 1.39- and 1.78-fold greater
odds, respectively, of having psoriasis than children with
normal weight [120]. Further, Paller et al. demonstrated the
increased risk of being overweight or obese in pediatric
psoriasis in a large international cross-sectional study in 5-
to 17-year-old children with psoriasis [10]. The odds ratios
(ORs) for obesity [body mass index (BMI) percentile
C95th] and excess adiposity (BMI percentile [85th) in
psoriatic children were 4.29 and 2.65, respectively. More
children with severe psoriasis [OR 4.92 (95 % CI
2.20–10.99)] than with moderate psoriasis [OR 3.60 (95 %
CI 1.56–8.30)] were obese compared with control subjects.
Waist circumference and waist-to-height ratio, surrogates
for central adiposity and sensitive indicators of metabolic
risk, were also seen more frequently increased in psoriatic
children [10].
The relationship between obesity and pediatric psoriasis
deserves further investigation. Pediatric psoriasis has been
associated with decreased quality of life as well as
decreased tendency to participate in physical activities
because of increased pruritus with sweating and increased
visibility of the psoriatic lesions to peers [7, 9, 12, 121].
These factors theoretically could contribute to pediatric
obesity, but only after the occurrence of psoriasis. On the
other hand, psoriasis could instead be a complication of
obesity, with systemic inflammation associated with obe-
sity predisposing to the occurrence of psoriasis [10, 122].
Becker et al. demonstrated in a pilot study that being
overweight or obese preceded psoriasis by at least 2 years
in 93 % of children with psoriasis [11]. In these children,
percentages of immediate family members with obesity
and psoriasis were 48 and 41 %, respectively. Although it
is unclear whether weight loss reduces psoriasis severity in
children, just as it remains controversial in adults, lifestyle
education and weight-loss programs in these families
should be recommended [11, 123].
In addition to obesity, the presence of the metabolic
syndrome is an issue in pediatric psoriasis patients. The
metabolic syndrome in children is defined as having at least
three of the following: (1) fasting triglycerides C1.1 mmol/
L; (2) high-density lipoprotein \1.3 mmol/L, except in
boys aged 15–19 years, in whom the cut-off point is
\1.2 mmol/L; (3) fasting glucose C6.1 mmol/L; (4) waist
circumference[75th percentile for age and gender; and (5)
systolic blood pressure [90th percentile for gender, age
and height (Fig. 1) [124]. In a small study in 20 children,
the prevalence of metabolic syndrome was significantly
higher in pediatric psoriasis patients (30 %) compared with
the age- and gender-matched control subjects (7.4 %). No
differences in BMI or individual components of metabolic
syndrome were found [125]. Childhood onset of psoriasis
does not seem to be an additional risk factor for the higher
prevalence of metabolic comorbidities and cardiovascular
disease in adulthood [126].
Pediatric psoriasis could have detrimental effects on
quality of life. Because of substantial developmental
changes in early life, children are a vulnerable group.
Psoriasis can disrupt their social relationships and interfere
with school and sport [7]. The Children Dermatology Life
Quality Index (CDLQI) was developed to allow quality-of-
life assessment in children with psoriasis and other skin
disorders [127]. Oostveen et al. conducted a prospective
observational study of children with psoriasis from a reg-
istry containing daily clinical practice data [9]. They
assessed the CDLQI in a cohort of 125 patients, finding that
psoriasis has a negative impact on quality of life. The
questions related to itching and their treatment regimens
seemed to have the highest impact on the quality of life of
these children. Effective interventions had a positive effect
on quality of life, primarily through improving complaints
of itch and sleep disturbance [9, 128].
Metabolic syndrome (pediatric definition):
The metabolic syndrome is defined as the presence of  3 or more of the following criteria:
• Hypertriglyceridemia: ≥ 1.1 mmol/L
• Low High-Density Lipoprotein (HDL) cholesterol: HDL < 1.3mmol/L 
(boys aged 15-19 years, < 1.17mmol/L)
• High fasting glucose: ≥ 6.1mmol/L
• Central obesity (waist circumference): > 75th percentile (for age and gender)
• Hypertension > 90th percentile (for age, gender and height)
Fig. 1 Pediatric definition of
the metabolic syndrome. Figure
adapted from de Ferranti et al.
[124]
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Previous research in adult populations reported psychiatric
symptoms and diagnoses, such as depression and anxiety, in
up to 60 % of psoriasis patients. Although studies regarding
psychiatric symptoms in pediatric psoriasis are limited, it is
known that pain, itching and the visible psoriasis lesions can
result in embarrassment, social discomfort and anxiety in
pediatric psoriasis patients [129, 130]. In line with these
findings, Kimball et al. demonstrated an increased risk of
developing depression, anxiety and bipolar disorder in psori-
atic children comparedwith control subjects [12]. In addition,
children suffering from psoriasis had a 47 % greater risk of
taking psychotropic medications. Since the rate of antide-
pressant and anxiolytic medication use is higher than the
incidences of depression and anxiety disorder in this study,
and psychotropic medications are more likely to be used for
more severe cases, the true incidence of psychiatric diagnoses
may be even higher [12]. The relationship between psoriasis
and depression and impaired quality of life in children has also
been reported by other research groups [8, 131].
9 Conclusion
Psoriasis begins in childhood in almost one-third of the
cases and is increasing in prevalence and incidence.
However, the evidence on treatment efficacy and safety is
still limited, and long-term data in pediatric patients are
lacking. A prospective, multicenter, international registry is
needed to evaluate these treatments in a standardized
manner and ultimately to develop international guidelines
on pediatric psoriasis.
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